Pompe disease: A neuromuscular disease with respiratory muscle involvement

Respiratory Medicine

Volumn 103, Issue 4, 2009, Pages 477-484

  Mellies, Uwe ^a   Lofaso, Frédéric ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b INSERM   (France)

Author keywords

Acid maltase deficiency; Glycogen storage disease type II; Pompe disease; Respiratory complications; Type II glycogenosis

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE; GAA PROTEIN, HUMAN;

BREATHING MUSCLE; CLINICAL FEATURE; CLINICAL TRIAL; DIAPHRAGM PARALYSIS; DRUG EFFICACY; DRUG SAFETY; GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LUNG GAS EXCHANGE; MOBILIZATION; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PHYSIOTHERAPY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY FUNCTION; REVIEW; ADULT; CHILD; COMPLICATION; DISEASE COURSE; GLYCOGEN STORAGE DISEASE TYPE II; INFANT; NEUROMUSCULAR DISEASES; RESPIRATION DISORDERS; RESPIRATORY INSUFFICIENCY;

ADULT; ALPHA-GLUCOSIDASES; CHILD; DISEASE PROGRESSION; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; NEUROMUSCULAR DISEASES; POSITIVE-PRESSURE RESPIRATION; RESPIRATION DISORDERS; RESPIRATORY INSUFFICIENCY; RESPIRATORY MUSCLES;

EID: 60749102886     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.12.009     Document Type: Review

References (57)

1. Hirschhorn R., and Reuser A.J.J. Glycogen storage disease type II: acid acid-glucosidase (acid maltase) deficiency. In: Scriver C.R., Sly W.S., Childs B., Beaudet A.L., Valle D., Kinzler K.W., and Vogelstein B. (Eds). The metabolic and molecular bases of inherited disease. 8th ed (2001), McGraw-Hill Medical 3389-3420
2. Raben N., Plotz P., and Byrne B.J. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2 (2002) 145-166
3. Ausems M.G., Verbiest J., Hermans M.P., et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 7 (1999) 713-716
4. Pinto R., Caseiro C., Lemos M., et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 12 (2004) 87-92
5. Kishnani P.S., Steiner R.D., Bali D., et al. Pompe disease diagnosis and management guideline. Genet Med 8 (2006) 267-288
6. Mellies U., and Dohna-Schwake C. Neuromuscular disorders. In: Hammer J., and Eber E. (Eds). Pediatric pulmonary function testing (2005), Karger, Basel 1-14
7. Burghaus L., Liu W., Neuen-Jacob E., Gempel K., and Haupt W.F. Glycogenesis Type II (M. Pompe). Selective failure of the respiratory musculature - a rare first symptom. Nervenartz 77 (2006) 181-186
8. Mellies U., Dohna-Schwake C., and Voit T. Respiratory function assessment and intervention in neuromuscular disorders. Curr Opin Neurol 18 (2005) 543-547
9. Howard R.S., Wiles C.M., Hirsch N.P., and Spencer G.T. Respiratory involvement in primary muscle disorders: assessment and management. Q J Med 86 (1993) 175-189
10. Sivak E.D., Salanga V.D., Wilbourn A.J., Mitsumoto H., and Golish J. Adult-onset acid maltase deficiency presenting as diaphragmatic paralysis. Ann Neurol 9 (1981) 613-615
11. Mellies U., Ragette R., Schwake C., Baethmann M., Voit T., and Teschler H. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 57 (2001) 1290-1295
12. Rosenow III E.C., and Engel A.G. Acid maltase deficiency in adults presenting as respiratory failure. Am J Med 64 (1978) 485-491
13. Sander H.W., Menkes D.L., Hood D.C., and Williams D.A. A 60-year-old woman with weakness, fatigue, and acute respiratory failure: case report and discussion of the differential diagnosis. Mil Med 163 (1998) 715-718
14. Culebras A. Diaphragmatic insufficiency in REM sleep. Sleep Med 5 (2004) 337-338
15. Pellegrini N., Laforet P., Orlikowski D., et al. Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease. Eur Respir J 26 (2005) 1024-1031
16. Kishnani P.S., Hwu W.L., Mandel H., et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148 (2006) 671-676
17. Hagemans M.L., Winkel L.P., Van Doorn P.A., et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 128 (2005) 671-677
18. Hagemans M.L., Hop W.J., Van Doorn P.A., and Reuser A.J. Van der Ploeg AT. Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 66 (2006) 581-583
19. Müller-Felber W., Horvath R., Gempel K., et al. Late onset Pompe disease: clinical and neuorphysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 17 (2007) 698-706
20. Van den Hout H.M., Hop W., van Diggelen O.P., et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112 (2003) 332-340
21. Akcam M. Infantile Pompe's disease presenting with pulmonary infections during the newborn period. Saudi Medical J 25 (2004) 2022-2023
22. Marsden D. Infantile onset Pompe disease: a report of physician narratives from an epidemiologic study. Genet Med 7 (2005) 147-150
23. Keunen R.W., Lambregts P.C., Op de Coul A.A., and Joosten E.M. Respiratory failure as initial symptom of acid maltase deficiency. J Neurol Neurosurg Psychiatry 47 (1984) 549-552
24. van der Ploeg A.T. Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives. Eur Respir J 26 (2005) 984-985
25. Escolar D.M., Wokke J.H., Pestronk A., Carter G.T., Jaffe K.M., and Laforêt P. Clinical presentation and disease progression in late-onset Pompe disease. Neuromuscular Disord 16 (2006) 654 [Abstract G.P.1 01]
26. American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 166 (2002) 518-524
27. Fromageot C., Lofaso F., Annane D., et al. Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular disorders. Arch Phys Med Rehabil 82 (2001) 123-128
28. Polkey M.I., Green M., and Moxham J. Measurement of respiratory muscle strength. Thorax 50 (1995) 1131-1135
29. Kang S.W., and Bach J.R. Maximum insufflation capacity. Chest 118 (2000) 61-65
30. Kang S.W., and Bach J.R. Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease. Am J Phys Med Rehabil 79 (2000) 222-227
31. Sivasothy P., Brown L., Smith I.E., and Shneerson J.M. Effect of manually assisted cough and mechanical insufflation on cough flow of normal subjects, patients with chronic obstructive pulmonary disease (COPD), and patients with respiratory muscle weakness. Thorax 56 (2001) 438-444
32. landelli L., Gorini M., Misuri G., et al. Assessing inspiratory muscle strength in patients with neurologic and neuromuscular diseases: comparative evaluation of two noninvasive techniques. Chest 119 (2001) 1108-1113
33. Trebbia G., Lacombe M., Fermanian C., et al. Cough determinants in patients with neuromuscular disease. Respir Physiol Neurobiol 146 (2005) 291-300
34. Dohna-Schwake C., Ragette R., Teschler H., Voit T., and Mellies U. IPPB-assisted coughing in neuromuscular disorders. Pediatr Pulmonol 41 (2006) 551-557
35. Dohna-Schwake C., Ragette R., Teschler H., Voit T., and Mellies U. Predictors of severe chest infections in pediatric neuromuscular disorders. Neuromuscul Disord 16 (2006) 325-328
36. Bach J.R., and Saporito L.R. Criteria for extubation and tracheostomy tube removal for patients with ventilatory failure. A different approach to weaning. Chest 110 (1996) 1566-1571
37. Sancho J., Servera E., Díaz J., and Marín J. Predictors of ineffective cough during a chest infection in patients with stable amyotrophic lateral sclerosis. Am J Respir Crit Care Med 175 (2007) 1266-1271
38. 2 retention in patients with neuromuscular disease. Chest 117 (2000) 447-453
39. Vercken J.B., Raphael J.C., de Lattre J., Fromageot C., and Fanjoux J. Adult maltase acid deficiency myopathy: treatment with long-term home mechanical ventilation. Biomed Pharmacother 42 (1988) 343-349
40. Hukins C.A., and Hillman D.R. Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy. Am J Repir Crit Care Med 161 (2000) 166-170
41. Simonds A.K., Muntoni F., Heather S., and Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax 53 (1998) 949-952
42. McFarlane H.J., and Soni N. Pompe's disease and anaesthesia. Anaesthesia 41 (1986) 1219-1224
43. Klingler W., Lehmann-Horn F., and Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord 15 (2005) 195-206
44. Kotani N., Hashimoto H., Hirota K., Muraoka M., and Matsuki A. Prolonged respiratory depression after anesthesia for parathyroidectomy in a patient with juvenile type of acid maltase deficiency. J Clin Anesth 8 (1996) 620
45. Ing R.J., Cook D.R., Bengur R.A., et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth 14 (2004) 514-519
46. Hagemans M.L., Janssens A.C., Winkel L.P., et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63 (2004) 1688-1692
47. Case L.E., and Kishnani P.S. Physical therapy management of Pompe disease. Genet Med 8 (2006) 318-327
48. Slonim A.E., Bulone L., Goldberg T., et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 35 (2007) 70-77
49. Kishnani P.S., Corzo D., Nicolino M., et al. Recombinant human acid (alpha)-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68 (2007) 99-109
50. Nicolino M. Alglucosidase alfa: first available treatment for Pompe disease. Therapy 4 (2007) 271-277
51. van der Ploeg A.T., and Marsden D.L. Physician reported outcomes of enzyme replacement therapy in older, severely affected patients with Pompe disease. Mol Genet Metabol 90 (2007) 257
52. Van den Hout J.M., Kamphoven J.H., Winkel L.P., et al. Long-term intravenous treatment of pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113 (2004) e448-e457
53. van der Ploeg A.T., and Marsden D.L. Response to treatment with Myozyme in juvenile patients with Pompe disease. Mol Genet Metabol 90 (2007) 257
54. Orlikowski D, Laforet P, Pellegrini N, et al. Effects of one year enzyme replacement therapy in severe form of late onset pompe disease. Severe Late Onset Treatment Study (French SLOTS) 60th Annual Meeting of American Academy of Neurology; Apr 12-19, 2008; Chicago, IL. Abstract P02.121.
55. van der Ploeg AT, Clemens PR, Corzo D, et al. Results from a randomized, double-blind, multicenter, multinational, placebo-controlled study of the safety and efficacy of Myozyme, recombinant human acid alpha-glucosidase (rhGAA), for the treatment of pompe disease in juveniles and adults [abstract]. Presented at the 60th Annual Meeting of American Academy of Neurology; Apri 12-19, 2008; Chicago, IL. Abstract LB2.001.
56. Koeberl D.D., Kishnani P.S., and Chen Y.T. Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis 30 (2007) 159-164
57. Okumiya T., Kroos M.A., Vliet L.V., Takeuchi H., Van der Ploeg A.T., and Reuser A.J. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab 90 (2007) 49-57